Cancer immunotherapy: moving forward with peptide T cell vaccines.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Opinion in Immunology

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.coi.2017.07.003PMID 28734176PMCID PMC5626598
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

  2017cited by this paper
• Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses

  2016cited by this paper
• Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer

  2016cited by this paper
• TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates

  2016cited by this paper
• Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

  2016cited by this paper
• Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

  2015cited by this paper
• Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial

  2015cited by this paper
• Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.

  2015cited by this paper
• Efficient delivery of antigen to DCs using yeast-derived microparticles

  2015cited by this paper
• c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma

  2015cited by this paper
• Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

  2014cited by this paper
• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

  2014cited by this paper
• BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses

  2013cited by this paper
• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

  2013cited by this paper
• The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells

  2013cited by this paper
• Exploiting the mutanome for tumor vaccination.

  2012cited by this paper
• TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

  2012cited by this paper
• NetMHCcons: a consensus method for the major histocompatibility complex class I predictions

  2011cited by this paper
• Identification and functions of pattern-recognition receptors.

  2010cited by this paper
• GM-CSF-secreting vaccines for solid tumors: moving forward.

  2010cited by this paper
• Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge.

  2010cited by this paper
• Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.

  2009cited by this paper
• Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice

  2009cited by this paper
• Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.

  2009cited by this paper
• MDA5/RIG-I and virus recognition.

  2008cited by this paper
• Intravaginal Immunization of Mice with Recombinant Salmonella enterica Serovar Typhimurium Expressing Human Papillomavirus Type 16 Antigens as a Potential Route of Vaccination against Cervical Cancer

  2008cited by this paper
• Peptide epitope identification for tumor-reactive CD4 T cells.

  2008cited by this paper
• CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity1

  2007cited by this paper
• Peptide Vaccination of Patients With Metastatic Melanoma: Improved Clinical Outcome in Patients Demonstrating Effective Immunization

  2006cited by this paper
• Tumor-specific Transplantation Antigens :

  2006cited by this paper
• Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation1

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN

  2004cited by this paper
• Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.

  2003cited by this paper
• Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

  2003cited by this paper
• Faculty Opinions recommendation of Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function.

  2003cited by this paper
• Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells

  2003cited by this paper
• Melacine®: an allogeneic melanoma tumor cell lysate vaccine

  2003cited by this paper
• Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.

  2002cited by this paper
• Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr.

  2001cited by this paper
• Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.

  1999cited by this paper
• CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ

  1999cited by this paper
• A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma.

  1999cited by this paper
• CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

  1999cited by this paper
• T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

  1998cited by this paper
• Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes

  1994cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides

  1987cited by this paper
• Tumor-specific transplantation antigens: G. H. A. Clowes memorial lecture.

  1968cited by this paper

• Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine

  2026cites this paper
• A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies

  2026cites this paper
• Design of a novel multiepitope vaccine against glioblastoma by in silico approaches

  2025cites this paper
• Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations

  2024cites this paper
• Immunotherapy targeting tumor‐associated antigen in a mouse model of head and neck cancer

  2024cites this paper
• A Review of Recent Advances in Peptide-Based Anticancer Therapeutic Vaccines and Nanovaccines in Prostate Cancer

  2023influential citation
• Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS

  2023cites this paper
• Recent Updates on Peptide Molecules in Drug and Vaccine Development.

  2023cites this paper
• Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape

  2023cites this paper
• Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches.

  2022cites this paper
• Mitogen‐activated protein kinase inhibition augments the T cell response against HOXB7‐expressing tumor through human leukocyte antigen upregulation

  2022cites this paper
• Protein Informatics and Vaccine Development: Cancer Case Study.

  2022cites this paper
• Altered MUC1 epitope‐specific CTLs: A potential target for immunotherapy of pancreatic cancer

  2022cites this paper
• Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors

  2022cites this paper
• The Cellular and Molecular Immunotherapy in Prostate Cancer

  2022cites this paper
• Emerging immune-based technologies for high-grade gliomas

  2022cites this paper
• Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity

  2022cites this paper
• Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma

  2022cites this paper
• Clinical significance of anticancer vaccines (literature review)

  2021cites this paper
• Vaccine Therapies for Cancer: Then and Now

  2021cites this paper
• Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model

  2021cites this paper
• The role of immunotherapy in advanced renal cell carcinoma

  2021cites this paper
• Uncovering the modified immunopeptidome reveals insights into principles of PTM-driven antigenicity

  2021cites this paper
• Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery

  2021cites this paper
• Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses

  2021cites this paper
• Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer

  2021cites this paper
• A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.

  2021cites this paper
• Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

  2021cites this paper
• Immunotherapy Resistance in Glioblastoma

  2021cites this paper
• Tumor Antigen-Based Nanovaccines for Cancer Immunotherapy: A Review.

  2021cites this paper
• Induction of Peptide-specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes

  2021influential citation
• Improving human cancer therapy through the evaluation of pet dogs

  2020cites this paper
• Immuno-informatics analysis and expression of a novel multi-domain antigen as a vaccine candidate against glioblastoma.

  2020cites this paper
• Improving human cancer therapy through the evaluation of pet dogs

  2020cites this paper
• Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer

  2020cites this paper
• T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity

  2020cites this paper
• High infiltration of B cells in tertiary lymphoid structures, TCR oligoclonality, and neoantigens are part of esophageal squamous cell carcinoma microenvironment

  2020cites this paper
• Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma

  2020cites this paper
• Activation of Human Vδ2+ γδ T Cells by Staphylococcus aureus Promotes Enhanced Anti-Staphylococcal Adaptive Immunity

  2020cites this paper
• Pathways involved in viral oncogenesis: New perspectives from virus-host protein interactomics.

  2020cites this paper
• Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy

  2020cites this paper
• Peptide-Based Vaccination Therapy for Rheumatic Diseases

  2020cites this paper
• An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer.

  2020cites this paper
• Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

  2020cites this paper
• Turning the corner on therapeutic cancer vaccines

  2019cites this paper
• Towards Breast Cancer Vaccines, Progress and Challenges.

  2019cites this paper
• Inducing Tumor Suppressive Microenvironments through Genome Edited CD47−/− Syngeneic Cell Vaccination

  2019cites this paper
• Phylogenetic and immunoinformatic analysis of VP4, VP7, and NSP4 genes of rotavirus strains circulating in children with acute gastroenteritis in Indonesia

  2019cites this paper
• Recent advances in nanomaterial-based synergistic combination cancer immunotherapy.

  2019cites this paper
• Peptides as cancer vaccines.

  2019cites this paper
• HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response

  2018cites this paper
• Disordered epitopes as peptide vaccines

  2018cites this paper
• Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy.

  2018cites this paper
• A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines

  2018cites this paper
• Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma

  2018cites this paper
• Antigen-adjuvant effects of icariin in enhancing tumor-specific immunity in mastocytoma-bearing DBA/2J mice.

  2018cites this paper
• Immunity against hepatitis E virus infection: Implications for therapy and vaccine development

  2018cites this paper
• Head and Neck Cancer Research and Support Foundations.

  2018cites this paper
• Developing peptide vaccines for breast cancer

  2018cites this paper
• CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells

  2018cites this paper
• Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

  2017cites this paper
• Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-lnduced Killer Cells

  2017cites this paper